top of page
Insights That Move the GPCR Field Forward
Read the latest analyses, interviews, and discoveries shaping the GPCR ecosystem — from research breakthroughs to biotech strategy.
GPCR News powered by our Strategic Partners
Blog: Blog2
Search
Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
August 2022 Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders "Geneva,...
GPCR News
Jul 31, 20221 min read
Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
August 2022 "Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company...
GPCR News
Jul 31, 20221 min read
Addex raises $4.2 million in equity financing
July 2022 "Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq:...
GPCR News
Jun 30, 20221 min read
Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
April 2022 Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics...
GPCR News
Mar 31, 20221 min read
Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
April 2022 Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment Of Schizophrenia & Other...
GPCR News
Mar 31, 20221 min read
Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
April 2022 Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study "Geneva, Switzerland,...
GPCR News
Mar 31, 20221 min read
Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10
March 2022 "Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company...
GPCR News
Feb 28, 20221 min read
Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia
January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator...
GPCR News
Jan 1, 20221 min read
Addex Raises $10 Million In Equity Financing
December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
GPCR News
Nov 30, 20211 min read
Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...
November 2021 Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has completed Phase 1 studies in...
GPCR News
Oct 31, 20211 min read
bottom of page